Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection 22-10-2024, 19:00

ProstaVive: We Tested It for 90 Days—Our Full Month-by-Month Review and the Shocking Truth About Long-Term Prostate Relief 10-04-2025, 22:50

Fortinet Reports Third Quarter 2023 Financial Results 3-11-2023, 03:05